Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
(2013) In EJNMMI Research 3(1).- Abstract
- Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3734153
- author
- Eriksson, Sophie LU ; Bäck, Tom ; Elgström, Erika LU ; Jensen, Holger ; Nilsson, Rune LU ; Lindegren, Sture and Tennvall, Jan LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- EJNMMI Research
- volume
- 3
- issue
- 1
- article number
- 23
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:23557183
- scopus:84876850544
- pmid:23557183
- wos:000209435800023
- ISSN
- 2191-219X
- DOI
- 10.1186/2191-219X-3-23
- language
- English
- LU publication?
- yes
- id
- 8f8c8939-94b4-4c96-808e-87c019826562 (old id 3734153)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23557183?dopt=Abstract
- date added to LUP
- 2016-04-01 14:48:50
- date last changed
- 2022-04-22 05:19:27
@article{8f8c8939-94b4-4c96-808e-87c019826562, abstract = {{Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.}}, author = {{Eriksson, Sophie and Bäck, Tom and Elgström, Erika and Jensen, Holger and Nilsson, Rune and Lindegren, Sture and Tennvall, Jan}}, issn = {{2191-219X}}, language = {{eng}}, number = {{1}}, publisher = {{BioMed Central (BMC)}}, series = {{EJNMMI Research}}, title = {{Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.}}, url = {{https://lup.lub.lu.se/search/files/4184006/4053663.pdf}}, doi = {{10.1186/2191-219X-3-23}}, volume = {{3}}, year = {{2013}}, }